Q-omics provides the consensus-scored BACE2 profile across patient tissues and cancer cell-line models. BACE2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, BACE2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, BACE2 RNA expression shows 18,391 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, COAD, and THYM as cancer lineages where BACE2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BACE2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BACE2 survival associations across molecular data types. BACE2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BACE2 RNA expression–survival associations across cancer types. High BACE2 expression shows unfavorable associations in CESC, ACC, UVM, LUAD, LGG and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for BACE2 RNA expression.
This table summarizes BACE2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for BACE2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BACE2 shows lower tumor expression in KIRC and higher tumor expression in COAD, KICH, LUAD, CHOL and READ. The COAD box plot shows higher BACE2 RNA expression in tumor versus normal tissue (log2 FC = +1.700, t-test p < 0.001).
This table shows molecular features associated with BACE2 in patient tissues and cancer cell lines. In patient samples, BACE2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BACE2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
